Status:
WITHDRAWN
The Use of a Continuous Glucose Monitoring System (Dexcom G6) in Hospitalized Patients for Acute Care
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Conditions:
Continuous Glucose Monitoring
Eligibility:
All Genders
18+ years
Brief Summary
The state of a coronavirus disease pandemic (COVID-19) was declared by the World Health Organization on March 11, 2020. Hospitalized patients receiving intravenous (IV) insulin therapy have been ident...
Eligibility Criteria
Inclusion
- Adult patients (≥ 18 years old) admitted to intensive care at the CHUM
- IV insulin infusion scheduled for a planned duration of at least 72 hours.
Exclusion
- Magnetic resonance imaging planned, which would require removing the sensor less than 72 hours after installation;
- Patient whose death is expected within the next 72 hours.
- Patient included in the LOVIT study due to the theoretical risk of interference with blood glucose measurements with the CMS device
Key Trial Info
Start Date :
July 27 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 11 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04385862
Start Date
July 27 2020
End Date
January 11 2021
Last Update
October 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier de l'Université de Montréal
Montreal, Canada